Viewing Study NCT01168050


Ignite Creation Date: 2025-12-24 @ 5:24 PM
Ignite Modification Date: 2025-12-28 @ 8:13 PM
Study NCT ID: NCT01168050
Status: UNKNOWN
Last Update Posted: 2011-02-08
First Post: 2010-07-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Sponsor: Assistance Publique - Hôpitaux de Paris
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module